Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.17 +0.81 (+1.23%)
Streaming Delayed Price Updated: 1:56 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
59 60 Next >
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
What's Going On With Novavax (NVAX) Stock?
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher on Monday after the company announced an amendment to its Canada supply agreement, under which the Government of Canada will pay Novavax $349.6... 
Via Benzinga
A Look Into AstraZeneca's Debt
Via Benzinga
AstraZeneca Unusual Options Activity
Via Benzinga
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
The company tested a treatment in combination with Daiichi Sankyo. 
Via Investor's Business Daily
AstraZeneca Unusual Options Activity For June 28
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
These Were Monday's 2 Stock Movers That Investors Cared About the Most
On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity. 
Via The Motley Fool
AstraZeneca Losses Leave The FTSE In The Red To Start July
Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns. 
Via Talk Markets
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
Price Over Earnings Overview: AstraZeneca
Via Benzinga
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
Deals, financings, trials and approvals for the week ending June 23. 
Via Talk Markets
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
From AstraZeneca
Via Business Wire
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high. 
Via The Motley Fool
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
This Is What Whales Are Betting On AstraZeneca
Via Benzinga
Is AstraZeneca a Top Stock to Buy Right Now?
The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead. 
Via The Motley Fool
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
From AstraZeneca
Via Business Wire
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues. 
Via Investor's Business Daily
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.